"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Pulmonary Arterial Hypertension (PAH) market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Pulmonary Arterial Hypertension (PAH) market." Pulmonary hypertension is a condition of increased blood pressure within the arteries of the lungs.[6] Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The global Pulmonary Arterial Hypertension (PAH) market is valued at 5960 million US$ in 2018 is expected to reach 9970 million US$ by the end of 2025, growing at a CAGR of 6.7% during 2019-2025. This report focuses on Pulmonary Arterial Hypertension (PAH) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pulmonary Arterial Hypertension (PAH) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: Actelion Gilead Sciences United Therapeutics GlaxoSmithKline Pfizer Bayer Arena ... Segment by Regions North America Europe China Japan Segment by Type Prostacyclin and Prostacyclin Analogs SGC Stimulators ERA PDE-5 Segment by Application Hospital Clinic
Table of Contents Executive Summary 1 Pulmonary Arterial Hypertension (PAH) Market Overview 1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) 1.2 Pulmonary Arterial Hypertension (PAH) Segment by Type 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Prostacyclin and Prostacyclin Analogs 1.2.3 SGC Stimulators 1.2.4 ERA 1.2.5 PDE-5 1.3 Pulmonary Arterial Hypertension (PAH) Segment by Application 1.3.1 Pulmonary Arterial Hypertension (PAH) Consumption Comparison by Application (2014-2025) 1.3.2 Hospital 1.3.3 Clinic 1.4 Global Pulmonary Arterial Hypertension (PAH) Market by Region 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global Pulmonary Arterial Hypertension (PAH) Market Size 1.5.1 Global Pulmonary Arterial Hypertension (PAH) Revenue (2014-2025) 1.5.2 Global Pulmonary Arterial Hypertension (PAH) Production (2014-2025) 2 Global Pulmonary Arterial Hypertension (PAH) Market Competition by Manufacturers 2.1 Global Pulmonary Arterial Hypertension (PAH) Production Market Share by Manufacturers (2014-2019) 2.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Manufacturers (2014-2019) 2.3 Global Pulmonary Arterial Hypertension (PAH) Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Pulmonary Arterial Hypertension (PAH) Production Sites, Area Served, Product Types 2.5 Pulmonary Arterial Hypertension (PAH) Market Competitive Situation and Trends 2.5.1 Pulmonary Arterial Hypertension (PAH) Market Concentration Rate 2.5.2 Pulmonary Arterial Hypertension (PAH) Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Pulmonary Arterial Hypertension (PAH) Production Market Share by Regions 3.1 Global Pulmonary Arterial Hypertension (PAH) Production Market Share by Regions 3.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Regions (2014-2019) 3.3 Global Pulmonary Arterial Hypertension (PAH) Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North ... | read more...